Lefamulin

Drug Profile

Lefamulin

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 11 Apr 2017 Nabriva Therapeutics completes enrolment in its phase III LEAP 1 trial for Community-acquired pneumonia
  • 08 Jan 2017 Phase-I clinical trials in Community-acquired pneumonia (In volunteers) in United Kingdom (IV) (NCT03131141)
  • 08 Jan 2017 Phase-I clinical trials in Community-acquired pneumonia (In volunteers) in United Kingdom (PO) (NCT03131141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top